Abstract
Despite the introduction of drug-eluting stents restenosis remains an important clinical problem. In this review we examine the role of plasminogen activator inhibitor-1 (PAI-1) in controlling restenosis after balloon angioplasty and stent implantation.
Keywords: Urokinase, vascular wall, restenosis, carotid artery ligation, VSMC proliferation
Current Drug Targets
Title: Plasminogen Activator Inhibitor-1 and Restenosis
Volume: 8 Issue: 9
Author(s): Nadish Garg and William P. Fay
Affiliation:
Keywords: Urokinase, vascular wall, restenosis, carotid artery ligation, VSMC proliferation
Abstract: Despite the introduction of drug-eluting stents restenosis remains an important clinical problem. In this review we examine the role of plasminogen activator inhibitor-1 (PAI-1) in controlling restenosis after balloon angioplasty and stent implantation.
Export Options
About this article
Cite this article as:
Garg Nadish and Fay P. William, Plasminogen Activator Inhibitor-1 and Restenosis, Current Drug Targets 2007; 8 (9) . https://dx.doi.org/10.2174/138945007781662355
DOI https://dx.doi.org/10.2174/138945007781662355 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Future Challenges for Microsomal Transport Protein Inhibitors
Current Vascular Pharmacology The Role of the Gut Microbiota in Energy Metabolism and Metabolic Disease
Current Pharmaceutical Design The Interplay of Marine Exposure in Gestational Diabetes
Current Women`s Health Reviews The Role of Recombinant Human Platelet-derived Growth Factor-BB (rhPDGF-BB) in Orthopaedic Bone Repair and Regeneration
Current Pharmaceutical Design The Triad: Erectile Dysfunction - Endothelial Dysfunction - Cardiovascular Disease
Current Pharmaceutical Design GSK3 Inhibitors in the Therapeutic Development of Diabetes, Cancer and Neurodegeneration: Past, Present and Future
Current Pharmaceutical Design Update on the Biologic Role of the Vitamin D Endocrine System
Current Vascular Pharmacology Emergence of Lipid-Based Vesicular Carriers as Nanoscale Pharmacotherapy in Rheumatoid Arthritis
Recent Patents on Nanomedicine Long-Term Effects of Perinatal Glucocorticoid Treatment on the Heart
Current Pediatric Reviews The Relationship Between HIV Infection and Cardiovascular Disease
Current Cardiology Reviews Ghrelin and Other Gastrointestinal Peptides Involved in the Control of Food Intake
Mini-Reviews in Medicinal Chemistry A Review on the Current Principles of Antibiotic Therapy for Diabetic Foot Infection
Infectious Disorders - Drug Targets Rapid and Simple Profiling of Lipoproteins by Polyacrylamide-Gel Disc Electrophoresis to Determine the Heterogeneity of Low-Density Lipoproteins (LDLs) Including Small, Dense LDL
Recent Patents on Cardiovascular Drug Discovery Recent Advances in Synthetic Chemistry of Diabetic Research
Mini-Reviews in Medicinal Chemistry Current Status of Complementary and Alternative Medicine in the Treatment of Rheumatic Disease Pain
Current Rheumatology Reviews Strategies for Diabetes Prevention Before and After Pregnancy in Women with GDM
Current Diabetes Reviews Genus Salacia: Chemical Composition, Antidiabetic Effect and other Bioactivities
The Natural Products Journal Biomarkers of Cardiovascular Risk in Haemodialysis Patients
Current Pharmaceutical Design How Effective are the Lipid Modifying Medicines at Preventing Coronary Heart Disease in Patients with the Metabolic Syndrome?
Vascular Disease Prevention (Discontinued) Vitamins and Type 2 Diabetes Mellitus
Endocrine, Metabolic & Immune Disorders - Drug Targets